<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01651390</url>
  </required_header>
  <id_info>
    <org_study_id>C1105</org_study_id>
    <nct_id>NCT01651390</nct_id>
  </id_info>
  <brief_title>Clinical Performance of the Pantera Lux Balloon Versus the Orsiro Stent in Patients With In-stent Restenosis.</brief_title>
  <acronym>BIOLUX-RCT</acronym>
  <official_title>BIOLUX RCT - Clinical Performance of the Pantera LUX Paclitaxel Releasing Balloon Versus the Drug Eluting Orsiro Hybrid Stent System in Patients With In-stent Restenosis - a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotronik AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biotronik AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine in a randomized controlled trial (RCT) whether percutaneous coronary
      intervention - in patients with in-stent restenosis in either bare metal stents or drug
      eluting stents - with the Pantera Lux balloon is angiographically non-inferior to
      percutaneous intervention with the Orsiro stent 6 months post-procedure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical investigation is an international, multi-center, randomized controlled trial
      with angiographic follow up at 6 months. Clinical follow ups will take place at 6, 12 and 18
      months.

      Up to 210 subjects will be block randomized 2:1 to receive the Pantera Lux balloon or the
      Orsiro stent and will be stratified according to diabetic status at screening.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Late lumen loss (in-stent)</measure>
    <time_frame>After 6 months.</time_frame>
    <description>In-stent late lumen loss is defined as the difference between minimal luminal diameter after procedure and at 6 months, as evaluated by offline quantitative coronary angiography (QCA).
In-stent:
Pantera Lux balloon: In-stent is defined as from (proximal) shoulder to (distal) shoulder of the dilated balloon.
Orsiro stent: In-stent is defined as from (proximal) edge to (distal) edge of the implanted Orsiro stent.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent diameter stenosis in-stent and in-segment</measure>
    <time_frame>After 6 months.</time_frame>
    <description>Percent diameter stenosis is defined as the difference between reference vessel diameter and minimal lumen diameter divided by reference vessel diameter x100%. Angiographic parameters as evaluated by offline QCA.
In-segment:
Pantera Lux balloon: In-segment is defined as in-stent plus 5 mm distal and 5 mm proximal.
Orsiro stent: In-segment is defined as in-stent plus 5 mm distal and 5 mm proximal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Binary restenosis in-stent and in-segment</measure>
    <time_frame>After 6 months.</time_frame>
    <description>Binary restenosis is defined as ≥50% lumen diameter stenosis as evaluated by offline QCA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean lumen diameter in-stent and in-segment</measure>
    <time_frame>After 6 months.</time_frame>
    <description>Mean minimum lumen diameter derived from two orthogonal views as evaluated by offline QCA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of reoccurrence according to Mehran classification</measure>
    <time_frame>After 6, 12 and 18 months.</time_frame>
    <description>Type of reoccurrence according to Mehran classification (Mehran et al. Circulation 199; 100: 1872-1878) evaluated by offline QCA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion failure (TLF)</measure>
    <time_frame>After 6 and 18 months.</time_frame>
    <description>TLF is defined as a composite of cardiac death, any target vessel myocardial infarction (MI), coronary artery bypass graft (CABG) and clinically driven target lesion revascularization (TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel failure (TVF)</measure>
    <time_frame>After 6, 12 and 18 months.</time_frame>
    <description>TVF is defined as a composite of cardiac death, any target vessel myocardial infarction, coronary artery bypass graft and clinically driven target vessel revascularization (TVR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>After 6, 12 and 18 months.</time_frame>
    <description>According to Academic Research Consortium (ARC) definition (Cutlip et al. Circulation 2007; 115: 2344-2351).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure success</measure>
    <time_frame>During hospital stay or 7 days after procedure, whichever came first.</time_frame>
    <description>Procedure success defined as achievement of a final diameter stenosis of &lt;30% by QCA, using any percutaneous method, without the occurrence of death, MI, or repeat revascularization of the target lesion during the hospital stay or 7 days after procedure, whichever came first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device success</measure>
    <time_frame>1 day (During procedure)</time_frame>
    <description>Successful delivery of the balloon or stent to the target lesion site in the coronary artery; and appropriate balloon inflation and deflation or stent deployment; and successful removal of the balloon or the delivery system.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">231</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Restenosis</condition>
  <arm_group>
    <arm_group_label>Drug coated balloon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Percutaneous coronary intervention with the Pantera Lux drug coated balloon.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug eluting stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Percutaneous coronary intervention with the Orsiro drug eluting stent.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Percutaneous coronary intervention</intervention_name>
    <description>Up to 140 patients meeting the inclusion criteria and none of the exclusion criteria are randomly selected and stratified according to diabetic status at screening are treated with the Pantera Lux drug coated balloon.</description>
    <arm_group_label>Drug coated balloon</arm_group_label>
    <other_name>Pantera Lux drug coated balloon</other_name>
    <other_name>Paclitaxel</other_name>
    <other_name>BTHC (Butyryltri-n-hexyl Citrate)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Percutaneous coronary intervention</intervention_name>
    <description>Up to 70 patients meeting the inclusion criteria and none of the exclusion criteria are randomly selected and stratified according to diabetic status at screening are treated with the Orsiro drug eluting stent.</description>
    <arm_group_label>Drug eluting stent</arm_group_label>
    <other_name>Orsiro drug eluting stent</other_name>
    <other_name>Orsiro hybrid drug eluting stent system</other_name>
    <other_name>Sirolimus eluting stent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject has provided a written informed consent

          2. Subject ≥ 18 years

          3. Clinical evidence of ischemic heart disease and/or a positive functional study, stable
             or unstable angina pectoris or documented silent ischemia

          4. Subject eligible for percutaneous coronary intervention

          5. Subject acceptable candidate for coronary artery bypass surgery

          6. Subject with an in-stent restenotic lesion* in either a bare metal stent or drug
             eluting stents (Mehran class I, II, III, IV - Mehran et al. Circulation 199; 100:
             1872-1878). *Target lesion

          7. Subjects with a maximum of 2 target lesions. In case of 2 target lesions, both lesions
             must be either in bare metal stents or drug eluting stents, and must treated during
             the same session with the same type of device as per randomization outcome, e.g. drug
             eluting stent.

          8. Target reference vessel diameter (visual estimation): ≥ 2.0 and ≤ 4.0 mm

          9. Target lesion length (visual estimation): ≥ 6.0 and ≤ 28.0 mm

         10. Target lesion stenosis (visual estimation): &gt; 50 % and ≤ 100 %

         11. Target lesion in a native coronary artery

        Exclusion Criteria:

          1. Planned (staged) interventional treatment in the same vessel(s) as the target
             lesion(s) within 30 days pre- and/or post BIOLUX RCT index procedure.

          2. Evidence of acute ST-segment-elevation myocardial infarction within 48 hours prior to
             index procedure according to the universal definition of myocardial infarction

          3. Subjects with acute cardiac decompensation or acute cardiogenic shock

          4. Subject with a life expectancy of less than 18 month

          5. In the investigators opinion subject who will not be able to comply with the follow up
             requirements

          6. Impaired renal function (excluded are subjects in need of dialysis or subjects with a
             creatinine level ≥ 221 µmol per liter (2.5 mg per deciliter) within 72 hours of the
             intended treatment)

          7. Thrombus in the target vessel

          8. Target lesion located in left main coronary artery

          9. Documented left ventricular ejection fraction (LVEF) ≤ 30%

         10. Known allergies to: acetylsalicylic acid, clopidogrel, prasugrel, ticagrelor, heparin,
             contrast medium, sirolimus or similar drugs (i.e., ABT 578, biolimus, tacrolimus);
             CoCr, PLLA, silicon carbide

         11. Subject is receiving oral or intravenous immunosuppressive therapy (e.g., inhaled
             steroids are not excluded) or has known life-limiting immunosuppressive or autoimmune
             disease (e.g., human immunodeficiency virus, systemic lupus erythematosus, but not
             including diabetes mellitus)

         12. Subject currently enrolled in other investigational device or drug trial in which
             primary endpoint has not been reached

         13. Pregnant and/or breast-feeding females or females who intend to become pregnant during
             the time of the study

         14. Previously enrolled in this trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph K Naber, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Contilia Heart- and Vascular Center, Elisabeth Krankenhaus, Klara-Kopp-Weg 1, 45138 Essen, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitäts-Herzzentrum Freiburg-Bad Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart Center Segeberger Kliniken</name>
      <address>
        <city>Bad Segeberg</city>
        <zip>23795</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin, Charité Centrum 11 für Herz-, Kreislauf- und Gefäßmedizin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innere Medizin Kardiologie - Charité Centrum 11, Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kardiologie - Angiologie - Pneumologie, Klinikum Coburg</name>
      <address>
        <city>Coburg</city>
        <zip>96450</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Contilia Heart- and Vascular Center, Elisabeth Krankenhaus</name>
      <address>
        <city>Essen</city>
        <zip>45138</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Care Center Prof. Mathey, Prof. Schofer</name>
      <address>
        <city>Hamburg</city>
        <zip>22527</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kardiologie /Intern. Intensivmedizin, Johannes Wesling Klinikum Minden</name>
      <address>
        <city>Minden</city>
        <zip>32429</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Schwabing</name>
      <address>
        <city>Munich</city>
        <zip>80804</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMU - Klinikum der Universität München</name>
      <address>
        <city>Munich</city>
        <zip>81337</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Bogenhausen</name>
      <address>
        <city>Munich</city>
        <zip>81925</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster, Klinik für Kardiologie</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innere Medizin III Kardiologie, Kliniken Villingen</name>
      <address>
        <city>Villingen-Schwenningen</city>
        <zip>78050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology, Pauls Stradins Clinical University Hospital</name>
      <address>
        <city>Riga</city>
        <zip>LV-1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Latvia</country>
  </location_countries>
  <reference>
    <citation>Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW; Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007 May 1;115(17):2344-51.</citation>
    <PMID>17470709</PMID>
  </reference>
  <reference>
    <citation>Mehran R, Dangas G, Abizaid AS, Mintz GS, Lansky AJ, Satler LF, Pichard AD, Kent KM, Stone GW, Leon MB. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation. 1999 Nov 2;100(18):1872-8.</citation>
    <PMID>10545431</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2012</study_first_submitted>
  <study_first_submitted_qc>July 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2012</study_first_posted>
  <last_update_submitted>September 23, 2016</last_update_submitted>
  <last_update_submitted_qc>September 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Restenosis</keyword>
  <keyword>Drug coated balloon</keyword>
  <keyword>Drug eluting stent</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Sirolimus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Restenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

